GLP-1-based clinical therapies have firmly established their importance among the therapeutical approaches available for the treatment of type 2 diabetes [40–42]; their action is exerted by potentiating glucose-stimulated insulin secretion. The gene discussed is INS; the disease is type 2 diabetes mellitus.